Saturday, October 31, 2026

IDEO's Revenue Falls 67% as AI Dismantles the Global Design Consultancy Model

IDEO's annual revenue has collapsed from $300M to under $100M — a 67% decline driven by generative AI tools now handling design work in-house. The shift is structural: what once required agency teams now runs on a single AI subscription. Mid-tier design consultancies worldwide, particularly those serving fintech, face the same displacement pressure.

LM Salvado
LM Salvado

May 18, 2026

IDEO's Revenue Falls 67% as AI Dismantles the Global Design Consultancy Model
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
1 The firm, long considered the global benchmark for human-centered design, is the clearest signal yet that AI has structurally dismantled the creative consultancy model.

Product and graphic design job postings have dropped sharply across multiple firms.1 Companies that once outsourced to agencies now deploy AI tools internally. One in-house operator with an AI subscription replaces what previously required an agency team.

The economics that sustained design consultancies for decades no longer hold. Generative image platforms, UI automation tools, and AI-assisted prototyping have compressed timelines and costs. The price premium agencies commanded — built on specialist labor and long project cycles — cannot compete with software-driven alternatives.

The pattern is global. In London, Singapore, São Paulo, and Dubai, agencies built on UX and product design contracts face identical pressure. Clients across sectors are pulling spend inward. As AI embeds into in-house product workflows, external agency retainers contract.

Fintech is particularly exposed worldwide. UX and product design were historically outsourced to specialists across financial services markets. AI tools now produce comparable output faster and cheaper. Agencies that built recurring revenue on those contracts face structural displacement, not a temporary budget cycle.

Design is not the first creative sector to absorb this. Stock photography collapsed first. Copywriting followed. Basic illustration came next. Design consultancies — with higher price points and longer engagement cycles — absorbed the shock more slowly. The IDEO numbers suggest that buffer is gone.

Continued revenue declines across human-centered design firms are expected globally.1 M&A consolidation or outright closures among mid-tier agencies are likely to follow — not only in the United States but across the major design markets of Western Europe and Asia-Pacific.

The roles that survive will cluster at two ends: high-level creative strategy and brand direction on one side, AI toolchain operators on the other. The mid-tier agency layer between them is contracting fast, on every continent.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com